Tempus projects $1.60B-$1.605B 2026 revenue while targeting $65M adjusted EBITDA, backed by BMS collaboration (NASDAQ:TEM)
· seekingalpha.com
Tempus AI Q3 2026 earnings: higher guidance, EBITDA inflection, BMS data deal, and 2027 oncology pricing tailwinds.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...